Cipher Pharmaceuticals Inc T.CPH

Alternate Symbol(s): CPHRF

Healthcare

Cipher Pharmaceuticals Inc. is a specialty pharmaceutical company with a diversified portfolio of commercial and early to late-stage products, mainly in dermatology. The Company acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and markets those products in Canada, the United States, and South America. Its dermatology products include Actikerall, Epuris, and Vaniqa. Its hospital acute care products include Aggrastat and Brinavess. Its out-licensed products include Absorica, ConZip and Lipofen. Durela is its specialty medicine. Its product pipeline includes MOB-015, CF-101, and DTR-001. It delivers novel products to healthcare professionals and patients in Canada in a range of therapeutic areas, including dermatology, women’s health, urology and others. It also has the Natroba operations and global product rights to Natroba and its authorized generic Spinosad, a topical treatment for both head lice and scabies.

TSX:CPH - Post by User

Cipher Pharmaceuticals Inc > Debt-Free CPH: At 1.5 times its 2020 EBITDA And The Buyback

<< Previous

Bullboard Posts

Next >>

Comment by faraj69on Feb 25, 2021 8:24am

120 Views

Post# 32656029

RE:RE:RE:RE:Debt-Free CPH: At 1.5 times its 2020 EBITDA And The Buyback

Shutup Stockfy there's no demand for this stock. Doesn't matter how many shares outstanding. There's no demand left and the demand they did have, they left because of the way Craig runs this zombie of a company. Keep posting your garbage stockfy it isn't going to change the share price.

<< Previous

Bullboard Posts

Next >>

Advancing flagship Ishkõday Gold Project in Ontario